ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Azitra Inc

Azitra Inc (AZTR)

0.4269
-0.0119
(-2.71%)
Closed December 17 3:00PM
0.4199
-0.007
(-1.64%)
After Hours: 5:54PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.4199
Bid
-
Ask
-
Volume
433,095
0.4001 Day's Range 0.455505
0.415 52 Week Range 68.40
Market Cap
Previous Close
0.4388
Open
0.44
Last Trade
396
@
0.4269
Last Trade Time
Financial Volume
US$ 183,183
VWAP
0.422962
Average Volume (3m)
168,868
Shares Outstanding
7,626,056
Dividend Yield
-
PE Ratio
-0.25
Earnings Per Share (EPS)
-1.66
Revenue
686k
Net Profit
-12.64M

About Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library ... Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Azitra Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AZTR. The last closing price for Azitra was US$0.44. Over the last year, Azitra shares have traded in a share price range of US$ 0.415 to US$ 68.40.

Azitra currently has 7,626,056 shares outstanding. The market capitalization of Azitra is US$3.35 million. Azitra has a price to earnings ratio (PE ratio) of -0.25.

AZTR Latest News

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates PR Newswire BRANFORD, Conn., Nov. 12, 2024 BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE...

Azitra to Present at BIO-Europe 2024

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company will present...

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company has been...

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking...

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0796-15.93593593590.49950.5050.4151309350.45968965CS
4-0.0351-7.714285714290.4550.52710.4151104790.47862744CS
12-0.1493-26.22979620520.56920.6340.4151688680.51557967CS
26-3.9301-90.34712643684.35120.41520007843.18331107CS
52-35.2801-98.823809523835.768.40.41513739494.23748022CS
156-127.3801-99.6714397496127.8155.40.4159209244.87767015CS
260-127.3801-99.6714397496127.8155.40.4159209244.87767015CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SYNXSilynxcom Ltd
US$ 3.97
(37.46%)
484.7k
OSTXOS Therapies Incorporated
US$ 4.71
(35.34%)
670.66k
YCBDcbdMD Inc
US$ 0.438999
(29.12%)
1.81M
CVMCel Sci Corporation New
US$ 0.7636
(17.48%)
848.25k
MRTMarti Technologies Inc
US$ 3.20
(15.11%)
82.17k
UAVSAgEagle Aerial Systems Inc
US$ 5.545
(-18.70%)
1.34M
TMFMMotley Fool Midcap Growth ETF
US$ 26.84
(-14.30%)
12.33k
UMACUnusual Machines Inc
US$ 11.307
(-13.62%)
3.99M
MYNDMynd ai Inc
US$ 1.871
(-13.38%)
96.07k
MMAMixed Martial Arts Group Limited
US$ 1.25
(-12.59%)
20.55k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 1.9248
(-7.24%)
95.77M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 3.75
(2.60%)
70.62M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 31.13
(-4.24%)
64.5M
SPYSPDR S&P 500
US$ 604.29
(-0.41%)
54.97M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 5.84
(1.39%)
52.47M

AZTR Discussion

View Posts
Monksdream Monksdream 1 month ago
AZTR, new 52/low
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
AZTR new 52 week low
πŸ‘οΈ0
herbied47 herbied47 3 months ago
AZTR 800k cash on hand from Q2 balance sheet and $10M from recent offering… after recent cash burn currently $9M cash on hand and currently trading at $4M market cap. BUY!
πŸ‘οΈ0
herbied47 herbied47 3 months ago
Online surveys are more lucrative then this mess.
πŸ‘οΈ0
herbied47 herbied47 3 months ago
Swing idea. AZTR small float, recently received study may proceed letter from the FDA for INDA to treat skin rash from EGFR inhibitors, , recent offering at 1.50, recently announced three newly patents in US, China and Canada to treat inflammatory skin diseases, recent 1/30 reverse split, Maxim Group Buy rating, price target $3
πŸ‘οΈ0
herbied47 herbied47 3 months ago
Should be getting an update soon. Strong buy right here with this kind of low float.
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
https://finance.yahoo.com/news/azitra-announces-first-patient-dosed-123000947.html
👍️ 1
Viewmont Viewmont 4 months ago
Moving after hours, what's up?
πŸ‘οΈ0
herbied47 herbied47 4 months ago
Press releases left and right. Sabby closing their short position the other day was the first clue. This will trade not
north of $3.00 soon! Load up!
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
AZTR................................https://stockcharts.com/h-sc/ui?s=AZTR&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
mikey4 mikey4 4 months ago
Shoulda dumped, looked a gift horse in the mouth and said β€œno thanks.”
πŸ‘οΈ0
herbied47 herbied47 4 months ago
Gap fill. Going back up! $1.50 open
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
AZTR; Be very careful --- merely PHASE-1, & a RARE skin disorder to boot. (Ain't goin' nowhere.)
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Nice thanks
πŸ‘οΈ0
mikey4 mikey4 4 months ago
Another dilution guaranteed

This is the easiest to estimate as the average duration for each phase is known. Roughly these are;

*Discovery - 3 years

*Pre-clinical - 1 year

*Phase I - 1/1.5 years

*Phase II - 1.5/2.5 years

*Phase III - 2/4 years

*Filing - 0.75 years

These are rough of course. In particular orphan drugs tend to progress faster as they can combine clinical phases.
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Waiting on volume !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Just need some volume !
πŸ‘οΈ0
mikey4 mikey4 4 months ago
In 11,000 @0.63 here. Is this even close to accurate?

Here are the revenue forecasts for Azitra, Inc. (AZTR) for the next 5 years ΒΉ:
- *2024*: No forecast available
- *2025*: $3 million
- *2026*: $0
- *2027*: $0
- *2028*: $21 million
- *2029*: $93 million
- *2030*: $165 million
- *2031*: $229 million

Please note that these forecasts are subject to change and might not reflect the company's current financial situation.
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
I will love to see after-hours run, usually they are the best, patiently waiting !
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
Yes, let's!
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
https://finance.yahoo.com/news/azitra-inc-announces-q2-2024-222300234.html
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Let’s have a nice squeeze $$$
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
It's moving up! Let's go!
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Loaded and ready
👍️ 1
Viewmont Viewmont 4 months ago
Yup! it should start going back up! https://schrts.co/ZVhEAaat
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
I like this

Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones
Strengthened global intellectual property portfolio with newly granted and allowed patents
Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting
Presented positive preclinical data of ATR-12 and clinical design in Netherton Syndrome at the ASGCT Annual Meeting
Opened a Phase 1b clinical trial for ATR-12 for recruitment
👍️ 1
Viewmont Viewmont 4 months ago
$AZTR https://www.otcmarkets.com/filing/html?id=17752131&guid=y8O-kq652gSvB3h
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
$AZTR Trying to move up! And there's a lot of room to do so! IMO.

BRANFORD, Conn., July 25, 2024--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions.

The updated release reads:

AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION PUBLIC OFFERING

Azitra, Inc. (NYSE American: AZTR) ("Company"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of an aggregate of 6,665,000 shares of its common stock, and Class A warrants to purchase up to 13,330,000 shares of common stock, at a combined public offering price of $1.50 per share and accompanying warrants. The Class A warrant will have an initial exercise price of $1.50 per share, will be exercisable immediately upon issuance, and will expire on the fifth anniversary of the original issuance date.
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
$AZTR https://schrts.co/pStTnWQN
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Pressure building up !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
A run of this level will be epic !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Nice thanks
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
40s on the way !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 4 months ago
Not looking good, looks like 50s on the way, CEO dead silent !
πŸ‘οΈ0
PennyPusher786 PennyPusher786 4 months ago
Scam company. I'm 93 % down in only the past few months. Do not buy
πŸ‘οΈ0
PennyPusher786 PennyPusher786 4 months ago
Don't buy it
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
AZTR new 52 week low
πŸ‘οΈ0
herbied47 herbied47 5 months ago
https://ir.azitrainc.com/news-releases/news-release-details/azitra-inc-strengthens-global-intellectual-property-portfolio this was just days ago of which it hit $12 then. Shoot yes here!
πŸ‘οΈ0
PennyPusher786 PennyPusher786 5 months ago
Up 11% from the bottom though. A averaging down would've been nice for a quick 10% profit lol...

These pricks just did a share offering though. I have my eyes on GNS CEOS BNED for a near term move
πŸ‘οΈ0
PennyPusher786 PennyPusher786 5 months ago
Up 11% from the bottom though. A averaging down would've been nice for a quick 10% profit lol...

These pricks just did a share offering though. I have my eyes on GNS CEOS BNED for a near term move
πŸ‘οΈ0
PennyPusher786 PennyPusher786 5 months ago
They're doing it to secure their pockets. God forbid they should actually earn money for once.

Fricken credit lines, and share offerings. And nieve shareholders to foot the bill... The west is finished lol...
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 5 months ago
Same everywhere, I’m not sure how that even can be legal, check $SIDU they been doing this for the last 2 years, crazy !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 5 months ago
https://scr.zacks.com/news/news-details/2024/AZTR-Get-Some-Skin-in-the-Game-article/default.aspx
πŸ‘οΈ0
PennyPusher786 PennyPusher786 5 months ago
I would consider a provEN OTC ticker at this point such that has room to grow like $CEOS

These nasdaq bioplays suck... pure reverse Splits and share offerings and barely ever a buyout or product that comes to fruition. Just CEOs and management using retail money to keep their income rolling
πŸ‘οΈ0
PennyPusher786 PennyPusher786 5 months ago
These morons ran a reverse split to get the share price out of pennies, then a share offering after a run up to $12.... and immediately dumped it under $1 again.

May God curse the management with for stealing money from share holders and lining their pockets.

Disgusting
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 5 months ago
Loading the 52WL, gambling here lol .
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
AZTR new 52 week low
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 5 months ago
New lows everywhere !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 5 months ago
New 52WL after hours .96 !
πŸ‘οΈ0
FROZENFLAME FROZENFLAME 5 months ago
https://www.businesswire.com/news/home/20240725675771/en/
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock